AbbVie (NYSE:ABBV) Trading Down 1% – What’s Next?

AbbVie Inc. (NYSE:ABBV)’s stock price fell 1% during trading on Thursday . The stock traded as low as $241.20 and last traded at $243.6380. Approximately 4,257,962 shares traded hands during trading, a decline of 39% from the average daily volume of 7,008,278 shares. The stock had previously closed at $246.20.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported robust second-quarter results, with adjusted earnings and revenue exceeding consensus estimates. Revenue increased 10.2% year over year, supported by continued growth from key medicines, and management raised its revenue outlook. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Allergan Aesthetics’ supplemental application for BOTOX Cosmetic in jawline treatment has been accepted for FDA review. Approval could expand BOTOX Cosmetic’s U.S. addressable market and further diversify AbbVie’s aesthetics portfolio. AbbVie Wins FDA Review for BOTOX Cosmetic
• Positive Sentiment: Analyst sentiment remains supportive: Erste Group upgraded AbbVie to “buy,” while Cantor Fitzgerald raised its price target to $285. The company’s dividend growth record also continues to attract income-focused investors. Cantor Fitzgerald Boosts AbbVie Price Target
• Neutral Sentiment: Several analysts remain bullish, but valuation has become a concern after AbbVie’s rally. A high earnings multiple leaves less room for execution disappointments, particularly as the Apogee transaction moves toward integration. Prediction: AbbVie Will End the Year at This Price
• Negative Sentiment: AbbVie reduced its 2026 EPS outlook to account for the Apogee acquisition, offsetting the positive impact of strong quarterly performance and higher revenue guidance. This earnings-impact concern appears to be the primary reason shares are under pressure. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the Apogee acquisition. The additional debt increases financing costs and leverage, creating near-term pressure on earnings and raising execution risk. AbbVie Prices $9.9 Billion of Senior Notes

Analyst Ratings Changes

Several equities analysts have weighed in on ABBV shares. Piper Sandler restated an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research note on Tuesday, June 23rd. Royal Bank Of Canada raised their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Barclays boosted their target price on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $272.76.

AbbVie Trading Down 1.0%

The firm has a fifty day moving average of $240.90 and a two-hundred day moving average of $224.61. The company has a market cap of $430.46 billion, a PE ratio of 68.82, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s payout ratio is presently 195.48%.

Hedge Funds Weigh In On AbbVie

Hedge funds have recently made changes to their positions in the stock. ACT Advisors LLC. raised its stake in AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after purchasing an additional 41 shares in the last quarter. Willner & Heller LLC increased its holdings in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC raised its position in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after buying an additional 43 shares in the last quarter. Bank of Jackson Hole Trust lifted its holdings in shares of AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after acquiring an additional 44 shares during the last quarter. Finally, Leslie Global Wealth LLC grew its position in AbbVie by 1.5% in the second quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock worth $751,000 after acquiring an additional 44 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.